Tyrosine kinase inhibitorFDA-approvedFirst-line
Alecensa
Generic name: alectinib
How it works
Blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 50% of patients with ALK-positive NSCLC achieved an objective response, with median progression-free survival of approximately 11 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rare Genetic Changes Found in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Rare Lung Cancer Mutation Responds to New Treatment | Lung Cancer | lab-study | The patient achieved a durable partial response to lorlatinib (progression-free survival > 15 months). | Source → |
| Alectinib Improves Lung Cancer Outcomes in Some Patients | Lung Cancer | phase-3 | Alectinib improved progression-free survival (HR 0.41, 95%CI 0.31-0.55, p < 0.001) compared to crizotinib. | Source → |
| Rare Side Effect of Cancer Treatment Alectinib | Lung Cancer | observational | — | Source → |
| Alectinib Shows Better Results Than Ceritinib in Lung Cancer Study | Lung Cancer | observational | First-line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026) | Source → |
| Cancer Drugs Cross Placenta in Lab Study | Lung Cancer | lab-study | — | Source → |
| Alectinib's Effectiveness in Lung Cancer Fades Over Time | Lung Cancer | review | — | Source → |
| Alectinib's Side Effects Linked to Biotin Deficiency | Lung Cancer | lab-study | — | Source → |
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Alectinib and Genetic Variations in Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Researchers Explore How Immune Cells Affect Lung Cancer Treatment | Lung Cancer | observational | Progression-free survival on alectinib appeared longer in patients with high than in those with low CD8A expression; however, this difference was not statistically conclusive (HR, 0.49 [95% CI, 0.18-1.35]). | Source → |
| Study of Alectinib as Adjuvant Therapy for Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Alectinib Shows Benefit in Early-Stage Lung Cancer Treatment | Lung Cancer | phase-3 | Patients receiving alectinib had longer DFS versus those who received chemotherapy. | Source → |
| Rare Cancer Mutation Responds to Alectinib Treatment | Lung Cancer | observational | The patient achieved a durable response with a progression-free survival of nearly four years. | Source → |
| Alectinib Treatment Effective for Some Lung Cancer Patients | Lung Cancer | observational | The median maximum tumor reduction rates were 90.5% for patients with V1, 63.4% for patients with V2, and 98.0% for patients with V3. | Source → |
| Alectinib Therapy for Lung Cancer: A Single Case Study | Lung Cancer | observational | — | Source → |
| Woman with Lung Cancer Achieves Long-Term Remission with Personalized Treatment | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
| Rare Liver Problem in Lung Cancer Patients Taking Alectinib | Lung Cancer | observational | — | Source → |
| Comparing Chemotherapy and Alectinib for Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| Rare Lung Cancer Patient Responds to Targeted Therapies | Lung Cancer | observational | Alectinib achieved a nearly complete response for lung and brain lesions. | Source → |
| Long-term Survival Benefits of Sequential Cancer Treatment in China | Lung Cancer | observational | Estimated 5-year OS was 68.6% in the overall population. | Source → |
| Elderly Lung Cancer Patient Responds to Alternative Treatment | Lung Cancer | observational | He had a 60% reduction in targeted pulmonary, bone and node lesions. | Source → |
| Rare Side Effect of Cancer Treatment Identified | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.